跳轉至內容
Merck
全部照片(1)

文件

AP502P

Sigma-Aldrich

山羊抗人Igκ链抗体，HRP偶联，吸附物种

Chemicon®, from goat

同義詞:

Anti-Human Ig HRP, HRP Goat Anti-Human Ig

登入查看組織和合約定價
全部照片(1)

About This Item

分類程式碼代碼:
12352203
eCl@ss:
32160702
NACRES:
NA.41

生物源

goat

品質等級

100

共軛

peroxidase conjugate

抗體表格

affinity purified immunoglobulin

抗體產品種類

secondary antibodies

無性繁殖

polyclonal

物種活性

human

製造商／商標名

Chemicon®

技術

ELISA: suitable

運輸包裝

wet ice

目標翻譯後修改

unmodified

相關類別

一般說明

抗体分子通常包含与一对重链共价结合的两条免疫球蛋白轻链。免疫球蛋白轻链有两种类型，用希腊字母κ和λ表示。κ和λ轻链的长度约为250个氨基酸，平均质量约为25 kDa。在免疫球蛋白群体中发现的κ与λ的比例因物种而异。

特異性

与人κ轻链反应。可吸收带有λ轻链的人骨髓瘤蛋白和小鼠免疫球蛋白。

應用

ELISA：1：4,000-1：8,000。

最佳工作稀释度必须由最终用户进行确定。
山羊抗人Igκ链抗体，HRP偶联物，吸附物种可检测人Igκ链水平&已发表&经验证可用于ELISA。

外觀

通过亲和色谱法对与琼脂糖共价连接的κ轻链的合并人Igs进行纯化。液体50%甘油/50%PBS，pH7.4。

法律資訊

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our 產品選擇工具.

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類（WGK）

WGK 2

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Hyori Kim et al.
Oncology letters, 25(6), 236-236 (2023-05-08)
Anti-CD19 chimeric antigen receptor (CAR)-T cells have improved the outcomes of patients with B cell leukemia and lymphoma. However, their applications and positive outcomes remain limited. CAR-T cells are currently restricted to autologous blood as their source and their use
Ramin Dubey et al.
eLife, 9 (2020-05-21)
R-spondins (RSPOs) amplify WNT signaling during development and regenerative responses. We previously demonstrated that RSPOs 2 and 3 potentiate WNT/β-catenin signaling in cells lacking leucine-rich repeat-containing G-protein coupled receptors (LGRs) 4, 5 and 6 (Lebensohn and Rohatgi, 2018). We now
Ki Hyun Kim et al.
PLoS pathogens, 15(2), e1007375-e1007375 (2019-02-02)
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease localized to China, Japan, and Korea that is characterized by severe hemorrhage and a high fatality rate. Currently, no specific vaccine or treatment has been approved for this disease.
Jessica N Peel et al.
The Journal of clinical investigation, 134(8) (2024-03-12)
BACKGROUNDWeakly virulent environmental mycobacteria (EM) can cause severe disease in HLA-DRB1*15:02 or 16:02 adults harboring neutralizing anti-IFN-γ autoantibodies (nAIGAs). The overall prevalence of nAIGAs in the general population is unknown, as are the penetrance of nAIGAs in HLA-DRB1*15:02 or 16:02

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務